Vivace Therapeutics Raises $30M in Series C Financing – FinSMEs

▤ Summary

In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace. The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP. Led by Sofie Qiao, Ph.D., President and Chief Executive Officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need. Its compounds inhibit palmitoylation of members of the transcriptional enhanced associate domain (TEAD) protein family.

▦ Linked Companies